Cadrenal Therapeutics to Present at Emerging Growth Conference on July 18, 2024

Cadrenal Therapeutics, Inc., a biopharmaceutical firm based in Ponte Vedra, Florida, is making strides in the field of anticoagulation therapy with its development of tecarfarin. Tecarfarin is a new-generation, oral, and reversible Vitamin K Antagonist (VKA), aimed at preventing heart attacks, strokes, and fatalities due to blood clots in patients with specific, rare cardiovascular conditions. The company recently announced its participation in the upcoming Emerging Growth Conference, a virtual event that brings together institutional and retail investors.

The presentation by Cadrenal Therapeutics is scheduled for Thursday, July 18, 2024, at 4:15 pm ET. The event will be accessible via a webcast link provided on the company's investor relations page. For those unable to attend the live session, an archived version will be available on the same platform and the Emerging Growth YouTube Channel. Following the presentation, the company’s management team will be available for one-on-one virtual meetings with interested investors. These meetings can be arranged by contacting the Emerging Growth Conference representative or the company's investor relations team.

Cadrenal Therapeutics is focused on meeting the unmet needs in the field of anticoagulation therapy with tecarfarin. Tecarfarin has been developed as an oral and reversible anticoagulant to serve patients who require lifelong anticoagulation, particularly those with rare cardiovascular conditions. The FDA has granted tecarfarin orphan drug designation for the prevention of thrombosis and thromboembolism in patients with mechanical circulatory support devices, such as the left ventricular assist device (LVAD). Additionally, the FDA has awarded tecarfarin both orphan drug and fast-track designations for preventing systemic thromboembolism of cardiac origin in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib).

A key differentiator for tecarfarin is its unique metabolic pathway, which sets it apart from warfarin, the most commonly prescribed VKA. Tecarfarin’s different metabolic process potentially offers advantages in terms of safety and efficacy. The drug has undergone extensive clinical evaluation, with 11 human clinical trials involving over 1,000 participants. These trials, including Phase 1, Phase 2, and Phase 2/3 studies, have demonstrated that tecarfarin is generally well-tolerated among both healthy adults and patients with chronic kidney disease.

This innovative approach by Cadrenal Therapeutics aims to provide a significant improvement in the management of anticoagulation therapy for patients with specific cardiovascular needs. The company's ongoing engagement with both the medical and investment communities underscores its commitment to advancing tecarfarin through the necessary regulatory and developmental milestones.

Cadrenal Therapeutics continues to be at the forefront of developing solutions for patients with complex cardiovascular conditions, striving to address the gaps in current anticoagulation therapies. With tecarfarin, the company hopes to offer a safer and more effective option for preventing life-threatening blood clots, thereby improving patient outcomes and quality of life.